Mirati wins over a Chinese partner for KRAS hopeful, looking to tail Amgen's breakthrough win
In a gunshot heard across oncology, the FDA handed Amgen a breakthrough win for a first-of-its-kind KRAS inhibitor — once considered “undruggable” — late last week. The drug’s biggest competitor, not content to rest on its laurels, has now signed a major marketing deal in China as it eyes a filing of its own.
Mirati will take home $65 million in cash and up to $273 million in biobucks from China’s Zai Lab for an exclusive license to KRAS-G12C hopeful adagrasib in the Greater China region, the companies said Tuesday. The deal will also come with royalties worth somewhere in the “high-teens to low-twenties-percent.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
